Icahn: Biogen Idec Will Be Bought

In a call-in interview on CNBC yesterday, investor Carl Icahn, who recently pushed unsuccessfully for a sale of Biogen Idec (NASDAQ: BIIB), expressed his belief that the fundamentals are still there for the company to be sold. Icahn spoke about several issues, including the state of the stock market (“it doesn’t look good”), and on the Cambridge, MA-based biotech he was to the point: “with Biogen, I still have belief that, you know, it’s a great company and that somebody will buy them. And we’re still looking at that and still in contact on that.”

Bob is Xconomy's founder and chairman. You can email him at bbuderi@xconomy.com. Follow @bbuderi

Trending on Xconomy